Filter by:
  • Trial Status
  • Trial Phase
  • Age
  • Sex
  • Location

    location

    Clear All

About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

342,868 studies
in
216 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 08/05/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 08/05/2020.
Displaying: 5,085 trials in your specialties ()
View trials across your selected specialties

Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck
View Full Trial
INTERVENTION

Drug: Tremelimumab, Drug: MEDI4736, Drug: MEDI4736 + Tremelimumab

Eligibility
  • Ages: 18 to 96 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Research Site, Baltimore, Maryland, United States

Brief Summary

The purpose of this study is to determine the efficacy and safety of investigational medical products (MEDI4736 monotherapy, tremelimumab monotherapy, and MEDI4736 + tremelimumab combination therapy) in the treatment of patients with recurrent or metastatic carcinoma of the head and neck who have progressed during or after treatment with a platinum containing regimen for recurrent/metastatic disease.

Narcotic vs. Non-narcotic Pain Study Protocol

  • Status
    Active, not recruiting
  • Phase
    Phase 4
  • Condition
    Carpal Tunnel
View Full Trial
INTERVENTION

Drug: Narcotic, Drug: non-narcotic

Eligibility
  • Ages: 18 to 90 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

The Philadelphia Hand Center, Philadelphia, Pennsylvania, United States

Brief Summary

The purposes of this noninferiority randomized clinical trial are to: 1. determine whether the most commonly used commonly used non-narcotic analgesic (ibuprofen 600 mg + acetaminophen 325 mg) provides pain relief that is not unacceptably worse than the most commonly prescribed narcotic containing analgesic (hydrocodone 5 mg. + acetaminophen 325 mg, equivalent to Norco 5/325) in patients undergoing carpal tunnel release. 2. Determine whether the following covariates affect pain level following surgery or medication usage: gender, country (US/Canada), pre-operative CTS symptoms, site, workers compensation status and employment status (employed/self-employed/unemployed-able to work/unemployed-unable to work)

A Study of RO7239958 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers and Participants With Chronic Hepatitis B Virus Infection

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Hepatitis B Virus Infection
View Full Trial
INTERVENTION

Drug: RO7239958, Other: Placebo

Eligibility
  • Ages: 18 to 65 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
Locations

Acibadem City Clinic Tokuda Hospital Ead, Sofia, Bulgaria

Brief Summary

This study is designed to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple ascending doses in healthy volunteers (HV) and participants diagnosed with chronic hepatitis B (CHB).

A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis

  • Status
    Active, not recruiting
  • Phase
    Phase 3
  • Condition
    Progressive Multiple Sclerosis (PMS)
View Full Trial
INTERVENTION

Drug: Ocrelizumab

Eligibility
  • Ages: 18 to 65 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

MS Center of California, Newport Beach, California, United States

Brief Summary

This study is a prospective, multicenter, open-label, single-arm effectiveness and safety study in participants with progressive multiple sclerosis (PMS).

Long Term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Pulmonary Arterial Hypertension
View Full Trial
INTERVENTION

Drug: Ralinepag

Eligibility
  • Ages: 18 to 75 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

University of Alabama at Birmingham, Birmingham, Alabama, United States

Brief Summary

This study is an open-label extension study to determine the long-term safety and tolerability of APD811 in patients with WHO Group 1 PAH who have completed the Phase 2 study, APD811-003. Patients must have completed the APD811-003 study and must meet eligibility criteria for APD811-007.

Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression

  • Status
    Active, not recruiting
  • Phase
    Phase 3
  • Condition
    Bipolar Depression
View Full Trial
INTERVENTION

Drug: ITI-007, Drug: Placebo

Eligibility
  • Ages: 18 to 75 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Clinical Site, Rogers, Arkansas, United States

Brief Summary

The study will evaluate the efficacy and safety of ITI-007 adjunctive to lithium or valproate in a randomized, double-blind, parallel-group, placebo-controlled, multi-center study in patients diagnosed with Bipolar I or Bipolar II disorder having a major depressive episode.

Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
View Full Trial
INTERVENTION

Drug: AZD3759, Drug: AZD9291

Eligibility
  • Ages: 18 to 130 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Research Site, Los Angeles, California, United States

Brief Summary

This is the first time in patient study to assess the safety, tolerability and preliminary efficacy of AZD3759 in patients with advanced Non Small Cell Lung Cancer (NSCLC) In this study, patients with Leptomeningeal Metastasis and Brain Metastasis may also be enrolled to assess the anti-tumour efficacy, safety, pharmacokinetics and potential biological activity of AZD9291

Osimertinib Study in Indian Patients

  • Status
    Active, not recruiting
  • Phase
    Phase 4
  • Condition
    Non Small Cell Lung Cancer (NSCLC)
View Full Trial
INTERVENTION

Drug: Osimertinib

Eligibility
  • Ages: 18 to 99 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Research Site, Mumbai, Maharashtra, India

Brief Summary

This is a prospective, single-arm, multicenter, phase-IV study investigating the safety of osimertinib in Indian adult patients.

Cilostazol and Endothelial Progenitor Cell

  • Status
    Active, not recruiting
  • Phase
    Phase 4
  • Condition
    Myocardial Infarction, Acute
View Full Trial
INTERVENTION

Drug: Cilostazol Tablets, Drug: placebo, Drug: Aspirin, Drug: Clopidogrel

Eligibility
  • Ages: 20 to 70 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Brief Summary

To assess impact of adjunctive cilostazol on endothelial progenitor cell (EPC) mobilization in patients with acute myocardial infarction (To reveal the role of cilostazol in up-regulation of EPC count)

Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19)

  • Status
    Active, not recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    COVID-19
View Full Trial
INTERVENTION

Biological: SARS-CoV-2 convalescent plasma

Eligibility
  • Ages: 18 to 80 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Danderyd Hospital, Danderyd, Sweden

Brief Summary

There is currently no effective treatment for COVID-19 except best supportive care. The aim is assess the safety, tolerability and efficacy of convalescent plasma for treatment of patients with varying degrees of COVID-19 illness. Convalescent plasma has been shown to be safe and effective for treatment of several diseases. Preliminary data indicates that it is safe and effective for treatment of COVID-19. However, data is limited to small studies and case series on severely ill patients. The proposed study assesses the safety and efficacy earlier in the course of illness, in slightly less severe patients with the possibility of detecting less severe adverse events and the potential for early treatment to hinder the development of severe disease. Plasma is collected from consenting donors who have recovered from SARS-CoV-2.